Evidence map›Paper›PMID 25389285›Full record

ArticleJournal of the American Heart Association2014

Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.

Atsushi Tanaka, Shinsuke Yuasa, Giulia Mearini, Toru Egashira, Tomohisa Seki, Masaki Kodaira, Dai Kusumoto, Yusuke Kuroda, Shinichiro Okata, Tomoyuki Suzuki and 9 more

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Bioactive factors in endometriosis peritoneal fluid remodel human cardiomyocytes.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Atsushi TanakaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.) Department of Cardiovascular Medicine, Saga University, Saga, Japan (A.T., K.N.).
Shinsuke YuasaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Giulia MeariniDepartment of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (G.M., L.C.) DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Germany (G.M., L.C.).
Toru EgashiraDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Tomohisa SekiDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Masaki KodairaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Dai KusumotoDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Yusuke KurodaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Shinichiro OkataDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.) Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan (S.O., T.F.).
Tomoyuki SuzukiDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Taku InoharaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Takuro ArimuraDepartment of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan (T.A., A.K.).
Shinji MakinoDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Kensuke KimuraDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).
Akinori KimuraDepartment of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan (T.A., A.K.).
Tetsushi FurukawaDepartment of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan (S.O., T.F.).
Lucie CarrierDepartment of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (G.M., L.C.) DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Germany (G.M., L.C.).
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Japan (A.T., K.N.).
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan (A.T., S.Y., T.E., T.S., M.K., D.K., Y.K., S.O., T.S., T.I., S.M., K.K., K.F.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the accumulating genetic and molecular investigations into hypertrophic cardiomyopathy (HCM), it remains unclear how this condition develops and worsens pathologically and clinically in terms of the genetic-environmental interactions. Establishing a human disease model for HCM would help to elucidate these disease mechanisms; however, cardiomyocytes from patients are not easily obtained for basic research. Patient-specific induced pluripotent stem cells (iPSCs) potentially hold much promise for deciphering the pathogenesis of HCM. The purpose of this study is to elucidate the interactions between genetic backgrounds and environmental factors involved in the disease progression of HCM. METHODS AND

resultsWe generated iPSCs from 3 patients with HCM and 3 healthy control subjects, and cardiomyocytes were differentiated. The HCM pathological phenotypes were characterized based on morphological properties and high-speed video imaging. The differences between control and HCM iPSC-derived cardiomyocytes were mild under baseline conditions in pathological features. To identify candidate disease-promoting environmental factors, the cardiomyocytes were stimulated by several cardiomyocyte hypertrophy-promoting factors. Interestingly, endothelin-1 strongly induced pathological phenotypes such as cardiomyocyte hypertrophy and intracellular myofibrillar disarray in the HCM iPSC-derived cardiomyocytes. We then reproduced these phenotypes in neonatal cardiomyocytes from the heterozygous Mybpc3-targeted knock in mice. High-speed video imaging with motion vector prediction depicted physiological contractile dynamics in the iPSC-derived cardiomyocytes, which revealed that self-beating HCM iPSC-derived single cardiomyocytes stimulated by endothelin-1 showed variable contractile directions.

conclusionsInteractions between the patient's genetic backgrounds and the environmental factor endothelin-1 promote the HCM pathological phenotype and contractile variability in the HCM iPSC-derived cardiomyocytes.

Indexed as

Cell DifferentiationAnimalsBiomechanical PhenomenaCardiomegalyCardiomyopathy, HypertrophicCarrier ProteinsCase-Control StudiesCells, CulturedDose-Response Relationship, DrugEndothelin-1Gene-Environment InteractionGenotypeHumansInduced Pluripotent Stem CellsMice, Inbred NODMice, SCIDCarrier ProteinsEndothelin-1Myosin Binding Protein Cdisease modelingET‐1HCMiPS cellsMYBPC3

Identifiers

PMID25389285
PMCPMC4338713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.